-
24 June 2025 23:03:48
- Source: Sharecast

This announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the Financial Conduct Authority and not a prospectus. This announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares of Elixirr International plc in any jurisdiction, including in or into or from the United States of America, Australia, Canada, Japan, the Republic of South Africa or in any other jurisdiction.
24 June 2025
ELIXIRR INTERNATIONAL PLC
Publication of Prospectus
Elixirr International plc (AIM:ELIX) ("Elixirr", the "Company" or, together with its subsidiary undertakings, the "Group"), an established, global award-winning challenger consultancy, is pleased to announce the publication of a prospectus (the "Prospectus") in relation to the proposed admission of its ordinary shares (the "Ordinary Shares") to listing on the Equity Shares (Commercial Companies) Category of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the Main Market for listed securities of the London Stock Exchange (together, "Admission").
It is expected that: (i) Admission will take place at 8.00 a.m. on 1 July 2025; and (ii) the Ordinary Shares will be cancelled from trading on AIM at 8.00 a.m. on 1 July 2025. The last day of trading of the Ordinary Shares on AIM is therefore expected to be 30 June 2025.
Elixirr confirms that, to the best of its knowledge, all known and material IHT holders have now exited the Company's share register.
Elixirr is not offering any new Ordinary Shares nor any other securities in connection with the proposed Admission. Following Admission, the Ordinary Shares will continue to be registered with their existing ISIN of GB00BLPHTX84 and the TIDM will remain ELIX.
The Company's shareholders should consult their own professional advisers regarding the consequences of Admission for them.
The Prospectus has been approved by the FCA and will shortly be available to view on Elixirr's website, [https://www.elixirr.com/en-gb/investors]. A copy of the Prospectus will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
For enquiries, please refer to the Company's Investor Contacts page:
https://www.elixirr.com/investors/investor-contacts
Elixirr International plc +44 (0)20 7220 5410
Stephen Newton, Chief Executive Officer
Graham Busby, Deputy Chief Executive Officer
Nick Willott, Chief Financial Officer and Company Secretary
investor-relations@elixirr.com
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) +44 (0)20 7220 0500
Stephen Keys, Callum Davidson, Isaac Hooper (Corporate Finance),
Sunila De Silva (ECM)
Peel Hunt LLP (Sponsor & Joint Broker) +44 (0)20 7418 8900
Neil Patel, Ben Cryer, Alice Lane, Kate Bannatyne
About Elixirr International plc
Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies. Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr has been quoted on the AIM market of the London Stock Exchange since 2020. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.